LOG-I - Impact Study of LOG-AFTER Software on Long-term Monitoring of Former Patients (LOG-I - LOG-Impact Study)
Launched by UNIVERSITY HOSPITAL, ANGERS · Apr 14, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The LOG-I study is examining how a software called LOG-AFTER can help improve follow-up care for young people who have survived cancer. Childhood cancer survivors often need special attention because they are at a higher risk for health issues later in life. This study aims to understand if using this software can help ensure that survivors and their doctors keep track of important health check-ups and screenings that are recommended for their ongoing care.
To be eligible for this study, participants must have been treated for cancer or a blood-related cancer before the age of 25 and must not have any active disease or have been stable for at least five years. They also need to have a computer or smartphone with internet access and be willing to participate. Those who join can expect to use the LOG-AFTER software to manage their health care follow-up more effectively, with the added benefit of their doctors being notified about their care plan. This study is not yet recruiting participants, but it aims to help improve the quality of life for childhood cancer survivors by making sure they receive the right ongoing care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Previously treated for cancer or malignant hematological pathology before the age of 25
- • Without residual disease or with a stable disease without treatment for 5 years or more
- • Owning a computer, smartphone or equivalent I-Pad/tablet with internet access
- • Having signed the consent (or their parents if the patient is a minor, or a third party if necessary)
- • Having 3 or more recommended screenings in their survivorship care plan
- • No access created to LOG-AFTER before the study or having never connected after opening their account if opening an account dating back 24 months or more at the time of inclusion
- Exclusion Criteria:
- • Patient who has relapsed or developed a second cancer with a post-treatment delay \< 5 years
- • Patient not covered by a health insurance
- • Patient subject to a legal protection measure, patient deprived of liberty by judicial or administrative decision, patient subject to psychiatric care under duress
About University Hospital, Angers
The University Hospital of Angers is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital leverages its multidisciplinary expertise and state-of-the-art facilities to investigate new therapeutic approaches and improve patient outcomes. Committed to excellence in patient care and medical education, the University Hospital of Angers collaborates with a network of researchers and healthcare professionals to facilitate groundbreaking studies across various medical fields, ensuring rigorous adherence to ethical standards and regulatory compliance. Through its clinical trial initiatives, the institution aims to contribute significantly to the advancement of medical knowledge and the development of effective treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Angers, Maine Et Loire, France
Patients applied
Trial Officials
Charlotte DEMOOR-GOLDSCHMIDT, Dr
Principal Investigator
University Hospital of Angers
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported